ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

valbenazine

Also written as “Valbenazine”, “NBI-98854” and “MT-5199”.

Its studies are mostly in Tardive Dyskinesia · Tourette Syndrome · Schizophrenia · Huntington Disease · Dyskinesias, led by 2 companies.

Drug pageValbenazine: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 4, 201828 company-led studies, 2 open or runningNext primary completion: Apr 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Neurocrine Biosciencesits history only272 open or runningphase 4since Oct 4, 2018Dec 21, 2010Apr 2028phase 3 · NCT06312189
Tanabe Pharma10 open or runningphase 3since Jun 2, 2017Jun 2, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Tanabe Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 2, 2017First study: phase 3 study in Tardive DyskinesiaFirst studyNCT03176771 · 256 enrolled · Japan

TargetBeta

SLC18A2 →read by rule
“Synaptic vesicular amine transporter inhibitor; Synaptic vesicular amine transporter inhibitor”ChEMBL 37, by rule

Other programs on SLC18A2

ProgramCompanyFurthest phaseStudies
lisdexamfetamineruleTakedaphase 447
deutetrabenazineruleTeva Pharmaceutical Industriesphase 412

Studies

The one study Tanabe Pharma leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03176771Tardive Dyskinesia · Japan3CompletedSep 29, 2020256

How it is read

Names in the registry

  • “Valbenazine”, 15 entries
  • “NBI-98854”, 13 entries
  • “MT-5199”, 1 entry
  • “NBI-98854 50 mg capsule”, 1 entry
  • “NBI-98854 50 mg capsule once daily”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.